CASE REPORT
Antiresorptive-associated spontaneous fractures of both tibiae, followed by an atypical femur fracture during the sequential treatment with alendronate, denosumab then teriparatide

Juan Tan,1 Hiroshige Sano,2 Kenneth Poole3

SUMMARY
A 35-year-old man with juvenile idiopathic arthritis since childhood presented with bilateral atypical tibial fractures, followed by a later, single atypical fracture of the femur. The fractures were associated with 6 years of oral alendronate treatment immediately followed by subcutaneous denosumab therapy and later teriparatide therapy for osteoporosis. Atypical fractures are known to occur in the femur following bisphosphonate therapy; however, there are only a few documented cases of atypical fractures in the tibia. Our case highlights a rare but serious complication of a commonly prescribed antiresorptive agent. It also shows that teriparatide, while helpful in increasing bone mass, does not fully prevent the development of atypical fractures. Careful investigation should be considered in patients on long-term antiresorptive therapy presenting with bony tenderness to exclude an atypical fracture.

BACKGROUND
Juvenile idiopathic arthritis is associated with tibial stress fractures in children,1 but here we present a challenging case in an adult, where antiresorptive therapy and underlying inflammatory disease may have been involved in the pathogenesis of multiple lower limb atypical fractures. Bisphosphonates are widely prescribed to prevent and treat osteoporosis. They have a good safety profile and are highly effective in increasing bone mass and density, thereby reducing fragility fracture risk.2,3 As analogues of inorganic pyrophosphate, bisphosphonates readily integrate at bone surfaces and induce osteoclast apoptosis, thereby suppressing bone resorption and increasing bone mass. Denosumab is a monoclonal antibody that binds RANK-Ligand, thereby inhibiting the recruitment and formation of osteoclasts, increasing bone mass and reducing fragility fractures. Both are in the class of ‘antiresorptive drugs’, having effects on both resorption and subsequent bone formation. Paradoxically, long-term antiresorptive use might impair bone remodelling and repair, resulting in the progressive accumulation of microdamage and increasing the risk of low-turnover ‘atypical’ stress fractures.4–7 As the primary weight-bearing bone during bipedal walking, the upper mid-femur appears to be particularly susceptible to developing atypical stress fractures.8–13 Fractures in other long bones such as the tibia have only rarely been reported.14–18 We describe a case of a 35-year-old man with juvenile idiopathic arthritis since childhood who presented with bilateral atypical tibial fractures, followed by a later, single atypical fracture of the femur. The fractures were associated with 6 years of oral alendronate treatment immediately followed by subcutaneous denosumab therapy and later teriparatide therapy for osteoporosis.

CASE PRESENTATION
A 35-year-old Caucasian man with a history of glucocorticoid-induced osteoporosis secondary to juvenile and continuing adult severe inflammatory arthritis took alendronic acid (70mg) weekly for 6 years continuously. He presented with a symptomatic left anterior tibial stress fracture associated with slight anterior bowing of his tibia and evidence of endosteal oedema on MRI (figure 1). This was managed conservatively, but he presented 7 months later with worsening acute pain in his left leg while seated. On examination, he had bony tenderness of the left mid-distal tibia with difficulty weight-bearing. There was no history of falls or local trauma. Other relevant medications included fortnightly adalimumab (40mg), as well as one time per day leflunomide (20mg), prednisolone (15mg) and etodolac (600mg). There was no history of cigarette smoking, no relevant alcohol intake and his body mass index (BMI) was below 25. He was ambulant without aids prior to his stress fracture but walked with an antalgic gait due to severe arthritis affecting his ankles and knees bilaterally.

At presentation, the plain X-ray revealed an incomplete, non-displaced short oblique fracture in the anterior middle-third of the left tibia diaphysis associated at the point of maximal anterior bowing of the tibia, that is, in a region subjected to high tensile forces during gait (figure 2). Bone mineral density (BMD) T-scores using dual-energy X-ray absorptiometry (DEXA) were −3.0 at the neck of femur and −3.1 at the lumbar spine (a T-score of <2.5 is a diagnosis of osteoporosis). He was fitted with a fibreglass cast and further conservative management was tried. Before coming under our care, his osteoporosis therapy was switched to subcutaneous denosumab 60mg 6-monthly due to...
concerns that alendronic acid may have interfered with fracture healing. A time frame of the events following this fracture is available in figure 3.

He continued to exhibit poor fracture healing over a year later. X-rays showed that the fracture line was still visible, with ongoing pain and no evidence of bone union. Teriparatide injections were commenced. Adalimumab was increased to 40mg weekly due to significant joint pain from active arthritis. Etodolac was stopped. Two months later, he developed a strikingly similar atypical fracture, this time in his right tibia (figure 2). Both tibiae were fixed with anterior tibial plates and screws.

He presented again 4 months postrepair with spontaneous bilateral periprosthetic transverse fractures that occurred suddenly while walking up the stairs at work. The tibial plates were removed, and the tibiae were fixed with intramedullary nails instead. A subsequent review showed a good postoperative

result with the anterior bowing of his tibiae corrected after nailing. Adalimumab was switched to tocilizumab due to worsening arthritis, but teriparatide injections were stopped after 18 months as he developed recurrent infections around the injection site. A DEXA scan demonstrated that his Z-scores had improved to −2.3 at the lumbar spine but only to −2.8 at the femoral neck. He was commenced on risedronate 35mg once weekly to maintain BMD gains induced by teriparatide.

One and half years later, he sustained a right femoral fracture (figure 4) associated with, but not necessarily caused by, a fall from standing height. X-rays showed a short oblique fracture at the proximal femoral diaphysis with cortical beaking. The fracture was treated with intramedullary nail fixation. A transiliac crest bone biopsy was subsequently taken following double tetracycline labelling to assess bone turnover. There was no evidence of malignancy, osteomalacia nor absent populations of osteoclasts. Bone volume over total volume was 17.2% (normal range: 16.4%–24.8%). Tetracycline labelling showed normal mineralisation and high bone turnover, with no suggestion of oversuppression (figure 5).

OUTCOME AND FOLLOW-UP

Our patient has since recovered well from his fractures and continues to receive regular follow-up with his rheumatologist.
DISCUSSION

There is a growing body of evidence linking long-term bisphosphonate use with atypical femoral fractures. Although initial registry studies found no correlation between bisphosphonate use and the rate of subtrochanteric or femoral shaft fractures, such studies have been criticised for overrelying on diagnostic codes, which fail to adequately distinguish atypical femoral fractures from other fractures. Conversely, most studies utilising radiographic data have demonstrated a strong association between bisphosphonates and atypical femoral fractures. A subsequent meta-analysis assessing data from both registry and radiographic studies has also shown an increased risk of subtrochanteric, femoral shaft and atypical femoral fractures with bisphosphonate usage.

Atypical insufficiency fractures of the tibia, on the contrary, are much less common. There are only a few case reports available which describe insufficiency fractures occurring in the tibial diaphysis and metaphysis of patients on long-term bisphosphonate therapy (table 1). The American Society for Bone and Mineral Research (ASBMR) has specific guidelines, which delineate the criteria for atypical insufficiency fractures.

However, this definition is strictly limited to femoral fractures and is not designed for fractures in alternative sites. Save for its location in the distal tibia, our case matches all major and multiple minor ASBMR criteria for atypical fractures. Key features include presenting with bilateral transverse, non-comminuted tibial fractures following no trauma, with delayed fracture healing and prodromal pain for several months leading up to the fracture.

The pathogenesis of atypical tibial fractures is unclear. In our patient, abnormal anterior tibial bowing could have led to altered biomechanical forces across the tibia, resulting in the development of microfractures along the anterior cortex. These were mild bilateral shape abnormalities, which might have been caused by the effects of juvenile arthritis on bone development rather than a true deformity (such as congenital pseudoarthrosis). It has been hypothesised that micromovements within a fracture can inhibit cellular remodelling and that osteoclast-mediated widening of the fracture gap is required before bone formation can occur.

Excessive osteoclast inhibition through long-term bisphosphonate and antiresorptive therapy could therefore predispose to the development of atypical insufficiency fractures. The duration of bisphosphonate usage has been strongly correlated with the risk of atypical femoral fractures. In a recent large cohort study, it was found that patients on bisphosphonates for over 8 years were more than 40 times more likely to develop atypical femoral fractures compared with patients with less than 1 year of usage. However, care should be taken when extrapolating these findings to tibial fractures. There is no current consensus on how to mitigate the risk of atypical fractures in long-term treated patients such as ours, who have a very substantial burden of severe osteoporotic disease, ongoing moderate steroid usage and in whom most guidelines would advocate continual treatment rather than a bisphosphonate break.

Other risk factors that may have contributed to his atypical fractures include the corticosteroid use itself and inflammatory arthritis. Denosumab, while certainly useful in the treatment of osteoporosis and prevention of fragility fractures, might in his case have led to accumulation of microfractures through blocking RANK-Ligand. Denosumab-associated atypical fractures following treatment for osteoporosis have been previously reported although these cases are uncommon. The extent to which any or all of these risk factors may have contributed to the development of his fractures remains uncertain.

The other point of interest in our case is the development of an atypical femoral fracture after our patient was started on risedronate treatment following completion of teriparatide therapy. Teriparatide has been shown to be effective in improving bone mass and reducing fracture healing time in atypical fractures secondary to bisphosphonate usage. However, similar cases of atypical femoral fractures occurring with the recommencement of antiresorptive agents following teriparatide therapy have previously been reported. It has been suggested that teriparatide may not be fully able to counteract the long-term effects of bisphosphonates on bone or that the reintroduction of antiresorptives could also be implicated in the recurrence of atypical fractures. Histomorphometry of our patient’s iliac crest biopsy has shown no evidence of oversuppression of bone turnover to account for his atypical fracture. This runs contrary to several reports that have demonstrated markedly reduced bone turnover in bisphosphonate-treated patients suffering from atypical fractures. There has been a case report that has shown no evidence of adynamic bone in a patient with atypical femoral fractures; however, the biopsy specimen was taken from near the fracture.
## Table 1  Current published case reports on atypical tibial fractures associated with long-term bisphosphonate/antiresorptive use

| Case report       | Age (in years)/sex | Diagnosis                                      | Antiresorptive agent (duration) | Fracture site                        | Management                  |
|-------------------|--------------------|------------------------------------------------|---------------------------------|--------------------------------------|-----------------------------|
| Bissonnette et al 44  | 77, F              | Postmenopausal osteoporosis                     | Zoledronate (4 years)           | Left tibial diaphyseal fracture       | Intramedullary nail fixation |
| Breglia and Carter 15  | 48, F              | Rheumatoid arthritis, glucocorticoid-induced osteoporosis | Alendronate (12 years)          | Left tibial diaphyseal fracture       | Conservative                |
| Odvina et al 46, 17  | 54, F              | Postmenopausal osteopenia                       | Risedronate (3 years)           | Right pelvis and right tibia          | Not specified               |
| Imbuldeniya et al 47  | 76, F              | Rheumatoid arthritis, osteomalacia, glucocorticoid-induced osteoporosis | Alendronate (3 years), pamidronate (6 years) | Bilateral proximal tibial metaphyseal fractures | Conservative                |
| Schimpf et al 48  | 76, F              | Rheumatoid arthritis, glucocorticoid-induced osteoporosis | Risedronate (5 years), strontium ranelate (2 years), zoledronate (4 years), denosumab (2 years) | Bilateral distal tibial metaphyseal fractures | Tabolic plates+screws       |

## Learning points

- Atypical fractures in the tibia can be a potential complication of long-term antiresorptive therapy.
- Teriparatide, while helpful in increasing bone mass, does not fully prevent the development of an atypical fracture.
- Careful investigation should be considered in patients on long-term antiresorptive agents presenting with bony tenderness to exclude an atypical fracture.
- Appropriate ‘bisphosphonate holidays’ should be taken to minimise the risk of developing atypical fractures.

### References

1. Kueenmerle-Deschner JB, Dammann F, Niethammer D, et al. Stress fractures: diagnostic pitfalls in juvenile idiopathic arthritis. Rheumatology 2001;40:1313–4.
2. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348:1535–41.
3. Papaoloucs SE. Chapter 49. Bisphosphonates for Postmenopausal Osteoporosis. Primer on the metabolic bone diseases and disorders of mineral metabolism. John Wiley & Sons, Inc, 2008:237–41.
4. Mashiba T, Hirano T, Turner CH, et al. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 2000;15:163–20.
5. Odvina CV, Zerwekh JE, Rao DS, et al. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005;90:1294–301.
6. Viselkra M, Wilson D, McKlearn FE. Severely suppressed bone turnover and atypical skeletal fragility. J Clin Endocrinol Metab 2008;93:2948–52.
7. Wunts NB, Diab DL. Long-term use of bisphosphonates in osteoporosis. J Clin Endocrinol Metab 2010;95:1555–65.
8. Armamento-Villareal R, Napoli N, Panwar V, et al. Suppressed bone turnover during alendronate therapy for high-turnover osteoporosis. N Engl J Med 2006;355:2048–50.
9. Butler I, Tipping B, Bhatia R. Atypical femoral fractures. Journal of Endocrinology, Metabolism and Diabetes of South Africa 2013;18:125–7.
10. Chang ST, Tenforde AS, Grimsrud CD, et al. Atypical femur fractures among breast cancer and multiple myeloma patients receiving intravenous bisphosphonate therapy. Bone 2012;51:524–7.
11. Girgis CM, Sher D, Seibl MJ. Atypical femoral fractures and bisphosphonate use. N Engl J Med 2010;362:1848–9.
12. Giusti A, Hamdy NA, Papaoloucs SE. Atypical fractures of the femur and bisphosphonate therapy: a systematic review of case/case series studies. Bone 2010;47:169–80.
13. Kwek EB, Goh SK, Koh JS, et al. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury 2008;39:224–31.
14. Bissonnette I, April PM, Dumas R, et al. Atypical fracture of the tibial diaphysis associated with bisphosphonate therapy: a case report. Bone 2013;56:406–9.
15. Breglia MD, Carter JD. Atypical insufficiency fracture of the tibia associated with long-term bisphosphonate therapy. J Clin Rheumatol 2010;16:76–8.
16. Odvina CV, Levy S, Rao S, et al. Unusual midshaft fractures during long-term bisphosphonate therapy. Clin Endocrinol 2010;72:161–8.
17. Imbuldeniya AM, Jiwa N, Murphy JP. Bilateral atypical insufficiency fractures of the proximal tibia and a unilateral distal femoral fracture associated with long-term intravenous bisphosphonate therapy: a case report. J Med Case Rep 2012;6:50.
18. Schimpf R, Siekmann H, Bauer C, et al. Atypische distale Tibiafrakturen bei liegenden KTEP biegsows unter antiresorptiver Therapie. Der Orthopäde 2018;47:688–91.
19. Black DM, Kelly MP, Genant HK, et al. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med 2010;362:1761–7.
20. Vestergaard P, Schwartz F, Rejmark L, et al. Risk of femoral shaft and subtrochanteric fractures among users of bisphosphonates and raloxifene. Osteoporos Int 2011;22:993–1001.
21. Abrahamsen B, Eiken P, Eastell R. Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res 2009;24:1095–102.
